About CG Oncology

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.

At CG Oncology, we see a world where urologic cancer patients can benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life.

Our product candidate, cretostimogene grenadenorepvec, is an investigational engineered oncolytic immunotherapy (OIT). In BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), cretostimogene has shown clinical benefit and has been generally well tolerated as both a monotherapy and in combination with other therapies in clinical trials.